Hogy Medical Co Ltd

Hogy Medical maintains a strong liquidity position with a current ratio of 4.26, indicating the company can easily cover its short-term liabilities with its current assets. The company's cash and equivalents amount to ¥22.005 billion, which is a significant portion of its total assets of ¥97.895 billion. The liquidity_fpt metric further supports this, showing the company has sufficient short-term liquidity to meet its obligations without relying on external financing. In terms of profitability, Hogy Medical's return on equity (ROE) of 2.05% and return on assets (ROA) of 1.55% are below the industry median for medical equipment and supplies firms. The company's operating income of ¥1.996 billion and net income of ¥1.521 billion reflect a relatively modest profit margin compared to its revenue of ¥39.138 billion. This suggests that the company may be facing competitive pressures or cost inefficiencies that are limiting its profitability. Geographically, Hogy Medical's revenue is concentrated in Japan, with no significant international operations disclosed in the available data. The company's business is primarily driven by domestic demand for medical equipment and supplies. There is no indication of revenue diversification across multiple regions or product segments, which could expose the company to regional economic fluctuations. Looking ahead, Hogy Medical's growth trajectory appears to be modest. The company's capital expenditures of ¥5.307 billion in the most recent period suggest a focus on maintaining and expanding its existing operations rather than pursuing aggressive growth. Analysts have set a mean price target of ¥4,400.00, with a median of ¥4,400.00, indicating a neutral outlook for the stock. The lack of strong buy or buy recommendations from analysts further supports this cautious stance. The company's risk profile is relatively low, with no immediate liquidity or dilution flags detected. The debt-to-equity ratio of 0.18 indicates a conservative capital structure, with long-term debt of ¥13.669 billion representing a small portion of the company's total equity of ¥74.324 billion. The absence of dilution risk is also a positive factor, as the company has not issued additional shares recently, and there are no indications of future share offerings. Recent filings and transcripts do not reveal any significant events that would impact the company's operations or financial performance. The company's financial statements show consistent performance, with no material changes in its operating cash flow or free cash flow. The company's management has not disclosed any major strategic initiatives or capital projects that would alter its current trajectory.